Cannabidiol Delta-9-Tetrahydrocannabinol Ratio Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic cancer pain often fail to adequately manage pain, leading to unmet needs in pain suppression, and opioid-based therapies can cause severe side effects such as constipation, sedation, and respiratory depression.
Innovation Solution
A cannabis-based medicine containing a combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) in a predefined ratio, preferably 1:1, is administered to provide effective pain relief and reduce opioid-related side effects like constipation, with titratable dosage forms for personalized dosing and targeted delivery methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid-based drugs are administered at increased dosages to relieve cancer pain, then pain suppression is improved, but side effects such as constipation, sedation, and respiratory depression worsen
Solution Approach 1:
The patent combines cannabinoids (THC and CBD) with opioid-based analgesics to create a synergistic pain management regimen. This combination allows for reduced opioid dosage while maintaining effective pain control and minimizing side effects, as the cannabinoids provide complementary analgesic activity and modulate opioid receptor function.
Solution Approach 2:
The patent utilizes the ratio relationship between THC and CBD cannabinoids to optimize therapeutic effects. By adjusting the ratio parameter (e.g., 1:1, 2:1, 1:2), the formulation can modulate pain relief efficacy and side effect profiles, allowing personalized dosing strategies that balance pain control with minimization of harmful effects.
2Reliability
If THC is administered alone for pain relief, then analgesic effect is achieved, but unwanted side effects occur
Solution Approach 1:
The patent merges THC with CBD in a combined cannabinoid formulation. CBD acts as a functional antagonist to some of THC's unwanted side effects while maintaining the analgesic benefits. This combination provides a more balanced therapeutic profile compared to THC alone, reducing issues such as sedation, anxiety, and other adverse effects.
Solution Approach 2:
The patent employs a composite cannabinoid formulation containing both THC and CBD in defined ratios. This composite approach leverages the complementary pharmacological properties of both cannabinoids to achieve superior pain management with reduced side effects compared to single-cannabinoid therapies.
3Quantity of substance
If cannabis is administered via smoking to bypass first pass effect, then bioavailability is improved, but inhalation of carcinogens occurs
Solution Approach 1:
The patent employs an intermediary delivery system in the form of a controlled-release oral formulation. This intermediary approach allows for bypassing first-pass metabolism through sublingual or buccal administration, avoiding the need for inhalation while maintaining high bioavailability. The formulation acts as a mediator that delivers cannabinoids directly to the bloodstream through the mucous membranes.
Solution Approach 2:
The patent replaces the mechanical inhalation system with a chemical formulation system. Instead of requiring the patient to smoke or vaporize the substance, the invention uses a prepared medicinal formulation that can be administered orally or sublingually, eliminating the mechanical act of inhalation and its associated carcinogen exposure while maintaining effective drug delivery.
Data Source
AI summary
The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.